Cited by 108Pancreatic function and diabetesDiabetes Management and ResearchDiabetes Treatment and Management

Intranasal Insulin Suppresses Endogenous Glucose Production in Humans Compared With Placebo in the Presence of Similar Venous Insulin Concentrations

Dash, Satya, Xiao, Changting, Morgantini, Cecilia, Koulajian, Khajag, Lewis, Gary F.·2015·Diabetes

Abstract

Intranasal insulin (INI) has been shown to modulate food intake and food-related activity in the central nervous system in humans. Because INI increases insulin concentration in the cerebrospinal fluid, these effects have been postulated to be mediated via insulin action in the brain, although peripheral effects of insulin cannot be excluded. INI has been shown to lower plasma glucose in some studies, but whether it regulates endogenous glucose production (EGP) is not known. To assess the role of INI in the regulation of EGP, eight healthy men were studied in a single-blind, crossover study with two randomized visits (one with 40 IU INI and the other with intranasal placebo [INP] administration) 4 weeks apart. EGP was assessed under conditions of an arterial pancreatic clamp, with a primed, constant infusion of deuterated glucose and infusion of 20% dextrose as required to maintain euglycemia. Between 180 and 360 min after administration, INI significantly suppressed EGP by 35.6% compared with INP, despite similar venous insulin concentrations. In conclusion, INI lowers EGP in humans compared with INP, despite similar venous insulin concentrations. INI may therefore be of value in treating excess liver glucose production in diabetes.

Integrity signals

Registry

Crossref · 10.2337/db14-0685

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In healthy men, insulin action in the brain suppresses endogenous glucose production.

    “Studies performed in healthy men found that insulin action in the brain suppresses endogenous glucose production3,11”
  • Nasal insulin did not modulate endogenous glucose production under systemic fasting insulin concentrations in most clinical trials.

    “as nasal insulin did not modulate endogenous glucose production under systemic fasting insulin concentrations in most12,14, but not all, clinical trials11.”
  • The current study corroborates that insulin action in the human brain modulates peripheral insulin sensitivity.

    “The current study corroborates that insulin action in the human brain modulates peripheral insulin sensitivity3,4,11”
  • Insulin action in the human brain modulates peripheral insulin sensitivity.

    “The current study corroborates that insulin action in the human brain modulates peripheral insulin sensitivity3,4,11”
  • In pancreatic clamps with a primed, constant infusion of glucose tracers, IN administration of 40 IU insulin lispro compared with placebo suppressed endogenous glucose production only in normal-weight participants.

    “In the latter set of experiments, 83,84 the IN administration of 40 IU of insulin lispro, another rapid-acting insulin analogue, in comparison with placebo, suppressed endogenous glucose production only in the normal-weight participants.”

    From Intranasal insulin (2021) · cites this paper as [83]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Dash, S., Xiao, C., Morgantini, C., Koulajian, K., & Lewis, G. F.
Affiliations
University of Toronto (CA)
Corresponding author
Lewis, Gary F.
Venue
Diabetes
Published
2014-10-06
Volume
64
Issue
3
Pages
766-774
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2136915688
Cited by
108
References
28
Citations by year
2026: 3 · 2025: 4 · 2024: 12 · 2023: 5 · 2022: 6 · 2021: 14 · 2020: 10 · 2019: 12 · 2018: 6 · 2017: 16 · 2016: 7 · 2015: 12 · 2014: 1
FWCI
11.90
Type
journal article
Language
en
Open access
closed
Locations
  • Diabetes (publishedVersion)
  • PubMed (publishedVersion)
Funders
Eli Lilly and Company (F3Z-CA-O082)
Topics
  • Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
intranasal insulin, endogenous glucose production, hepatic glucose production, cerebrospinal fluid insulin, deuterated glucose, normoglycemia, diabetes treatment, liver glucose production
MeSH terms
Administration, Intranasal, Blood Glucose, Glucose, Humans, Hypoglycemic Agents, Insulin, Liver, Male, Middle Aged, Single-Blind Method, Cross-Over Studies, Healthy Volunteers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review